Editorial: AntibodyPlus therapeutics in oncology: innovative mechanisms, therapeutic strategies, and clinical advances

• by Yuanzhi Chen, Pengwei Ren, Heyu Chen, Maozhou He

• June 15, 2026

Oncology Organization and Oncologist Networks Under Medicare Advantage Plans

• by Xin Hu, Youngmin Kwon, Qinjin Fan, Kewei Sylvia Shi, Zhiyuan Zheng, Jingxuan Zhao, Joan L. Warren, K. Robin Yabroff, Zhanji Zhang, Xuesong Han, Changchuan Jiang

• June 15, 2026

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

• by Lixiao Shi, Dixiao Zhong, Ruihong Tang, Duanfang Shao, Xiang Cheng, Zhaoxia Zhang, Rong Liu

• June 15, 2026

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

• June 15, 2026

• 2 min